Antigen presentation has a central role in immunity. Antigens vary in chemical composition and origin. Distinct T cell populations distinguish these antigens and trigger tailored responses against each specific challenge. Underpinning this distinction are major histo compatibility complex (MHC) class I, MHC class II and MHC class I-like molecules, which present different types of antigens 1 . In turn, each antigenpresenting molecule follows a distinct intracellular traf ficking route to acquire its antigenic cargo at a particular location.
Antigen presentation has a central role in immunity. Antigens vary in chemical composition and origin. Distinct T cell populations distinguish these antigens and trigger tailored responses against each specific challenge. Underpinning this distinction are major histo compatibility complex (MHC) class I, MHC class II and MHC class I-like molecules, which present different types of antigens 1 . In turn, each antigenpresenting molecule follows a distinct intracellular traf ficking route to acquire its antigenic cargo at a particular location.
MHC class I molecules present peptides that are constitutively gen erated in the cytosol and transported into the endoplasmic reticulum (ER) 2 . The resulting complexes traffic to the plasma membrane, where they remain until the peptide dissociates, which causes unfolding, internalization and destruction of MHC class I in endosomal com partments 3 . MHC class II molecules associate constitutively with a ligand, the invariant chain (Ii), in the ER. The MHC class II-Ii com plexes traffic to endosomal compartments, where endocytosed pro teins are proteolyzed, producing peptides that replace Ii. The MHC class II-peptide complexes then traffic to the plasma membrane 4 . The MHC class I-like molecules of the CD1 family bind endogenous lipids in the ER and traffic to the plasma membrane. These complexes are then delivered to endosomal compartments, where the endogenous ligands are exchanged for new lipid antigens, allowing CD1 molecules to present ligands of exogenous origin 5 . Thus, MHC and CD1 mol ecules utilize a broad range of antigenpresentation strategies charac terized by their unique intracellular trafficking routes. Nevertheless, they all share two common features: (i) they constitutively acquire selfligands in the ER soon after synthesis, and (ii) they continually traffic to the cell surface, where they are expressed in high amounts even in the absence of infection.
MR1, an MHC class I-related molecule, presents a novel class of antigens that are released to the extracellular environment or the lumen of phagosomal compartments harboring microbes. These lig ands consist of VitB antigens [6] [7] [8] [9] and are recognized, bound to MR1, by MAIT cells 7, [10] [11] [12] . MAIT cells are abundant in humans, and although their role in health and disease remains unclear, their T cell antigen receptor (TCR)mediated activation and function are dependent on MR1 antigen presentation 13, 14 . Thus, infections with microorganisms that produce VitB antigens cause MAIT cell recruitment to and/or expansion at the site of infection in an MR1dependent manner, but infections with microorganisms that do not produce the ligands do not trigger TCRmediated MAIT cell activation [15] [16] [17] [18] .
Given the central role of presentation of VitB antigens in MAIT cell function, it is important to characterize the intracellular mechanisms involved. In the absence of infection, MR1 expression is ubiquitous A r t i c l e s but very low on the cell surface. It has been proposed that in these conditions MR1 traffics through endosomal compartments, where it binds unknown ligands that are subsequently presented on the plasma membrane 19 . Upon infection, the route followed by MR1 is also thought to involve passage through endosomal compartments, where MR1 molecules would acquire pathogenderived ligands and then traffic to the plasma membrane 19 . However, whether this is the pathway followed by MR1 to acquire and present VitB antigens has not been investigated, as these ligands were only recently identified as the physiological pathogenderived ligands of MR1 (refs. 6,7) .
We have determined the intracellular location where MR1 acquires VitB antigens, the trafficking pathway of the MR1VitB antigen complexes and their fate after expression on the plasma membrane. We show that MR1 is retained in the ER in a ligandreceptive con formation rather than bound to endogenous ligands, until suitable ligands capable of forming a Schiff base with MR1 allow the resulting complexes to traffic to the cell surface. These complexes are endo cytosed with kinetics independent of the affinity of the MR1ligand interaction and most are degraded intracellularly.
RESULTS

Presynthesized MR1 molecules present VitB antigens
The VitB antigens acetyl6formylpterin (Ac6FP) and 5(2oxo propylideneamino)6dribitylaminouracil (5OPRU) are MR1 lig ands that potently induce upregulation of MR1 at the cell surface 6, 7, 10 ( Fig. 1a) . To establish whether the MR1 molecules expressed on cells incubated with 5OPRU or Ac6FP were in complex with these ligands, we compared MR1 cell surface expression by flow cytom etry using two reagents: a panMR1-specific monoclonal antibody (mAb) (26.5) and a newly generated soluble αβTCR tetramer derived from a MAIT cell clone specific for MR1 associated to 5OPRU (Supplementary Fig. 1 ). In conditions where cells expressed high amounts of surface MR1 as detected with 26.5, only the cells exposed to 5OPRU bound the TCR tetramer (Fig. 1b) . This implies that the increase in MR1 surface expression induced by the ligands was attributable to their direct association to MR1 and not to an indirect induction of MR1 expression. Kinetically, MR1 surface expression was induced faster by 5OPRU than by Ac6FP, peaking at 4 h with 5OPRU and at 8-16 h with Ac6FP (Fig. 1a) . C1R cells transfected to overexpress MR1 (C1R.MR1) showed similar cell surfaceexpression kinetics to that of cells expressing endogenous MR1 (Supplementary Fig. 2 ), whereas endogenous MHC class I expression was not affected by culture with ligands ( Fig. 1a and Supplementary  Fig. 2 ). MR1 expression stabilized after the peak of induction in cells incubated continuously with Ac6FP but decreased in cells incubated with 5OPRU. This is attributable to Ac6FP having greater stability in culture medium than 5OPRU (data not shown).
Inhibiting protein exit from the ER with Brefeldin A (BFA) ablated the antigendependent increase in MR1 cell surface expression (Fig. 1a) . In contrast, inhibiting protein synthesis with cycloheximide (CHX) (Fig. 1c) had a negligible effect on the initial upregulation of MR1 and showed effects only after 2 h in cells incubated with Ac6FP, and not at all in cells incubated with 5OPRU (Fig. 1a) . These observations were reproduced in primary human cells; MR1 cell surface expression was low on primary human peripheral blood mononuclear cells (PBMCs) and bronchial epithelial cells but was upregulated in the presence of 5OPRU in a process that was fully inhibited with BFA but not CHX (Fig. 1d) .
We then analyzed MR1 presentation of natural riboflavinbased ligands produced by bacteria [6] [7] [8] [9] (Fig. 2) . More than 20% of C1R cells incubated with fluorescent (mCherry + ) Salmonella enterica serovar Typhimurium (STM) strains SL1344 (wild type) or HW101 (riboflavin pathway-deficient) harbored bacteria intracellularly (Fig. 2a,b) . Surface MR1 expression was unaffected by infection (Fig. 2a) . This was unsurprising, as the amount of ligand produced in the infected cells is probably too small to cause a net increase in surface MR1 detectable by flow cytometry. This result also showed that bacterial invasion is insufficient to cause MR1 upregulation; rather, ligand avail ability appears to be the limiting factor. We resorted to a more sensi tive assay to detect MR1 presentation of bacteriaderived ligands by PBMCs, namely activation of autologous MAIT cells 11 . This assay was at least tenfold more sensitive than measuring surface MR1 by flow cytometry (Fig. 2c) . We infected adherent PBMCs with STM strains SL1344 or HW101 in the presence or absence of BFA or CHX and fixed the infected cells to prevent further changes to MR1 expression or antigen presentation. The efficiency of infection was not affected by BFA or CHX treatment (Fig. 2d,e) . Infected cells were incubated with autologous PBMCs, and MAIT cell activation was assessed by measuring production of tumor necrosis factor (TNF) (Fig. 2e) . MR1 presentation was profoundly inhibited in infected antigenpresenting cells treated with BFA but much less so in their counterparts treated with CHX (Fig. 2e) . The effects of the two inhibitors on MAIT cell activation recapitulated observations of MR1antigen complex pres entation measured by flow cytometry (Fig. 1a,d and Supplementary  Fig. 2 ). These results suggest that primary cells or cell lines contain a reservoir of MR1 molecules in the ER that can present synthetic or bacterial VitB antigens even when protein synthesis is shut down.
MR1 is retained in the ER in the absence of exogenous ligand
To establish biochemically the origin and location of MR1 in cells before and after incubation with VitB antigens, we performed cell surface-protein biotinylation followed by precipitation of biotinylated proteins and MR1specific immunoblot analysis. To facilitate detection of the molecule, we performed this experiment first with C1R.MR1 cells. Cells incubated with Ac6FP or 5OPRU contained detectable amounts of MR1 on their plasma membranes, but their counterparts incubated without ligands did not (Fig. 3a, right) . In contrast, analysis of total MR1 (either biotinylated or not) immunoprecipitated from cell lysates revealed substantial amounts of MR1 in all samples (Fig. 3a,  left) . To address our hypothesis that the MR1 molecules are located in a preGolgi compartment in the absence of ligands, we treated the immunoprecipitates with endoNacetylglucosaminidase H (Endo H). This enzyme removes carbohydrates from glycoproteins that have not yet been processed during passage through the Golgi, reducing their molecular weight. The MR1 molecules in cells incu bated without ligands were sensitive to digestion with Endo H, but those in cells incubated with Ac6FP or 5OPRU were resistant (Fig. 3a, left) . The small amount of Endo H-sensitive MR1 in cells incubated with ligands probably represented recently synthesized molecules that had not yet bound ligand and left the ER because all of the surface (biotinylated) MR1 in these cells was Endo H resistant (Fig. 3a, right) . Similar observations were made with human PBMCs (Fig. 3b) , in which MR1 is expressed at much lower levels. The locali zation of MR1 was further analyzed by confocal microscopy, which showed that MR1 fused to GFP (MR1GFP) colocalized with an ER marker in cells not incubated with ligand but was localized on the plasma membrane in cells incubated with Ac6FP (Fig. 3c) . MR1GFP behaved similarly to wildtype MR1, remaining Endo H sensitive until MR1GFP-expressing cells were incubated with ligands ( Supplementary Fig. 3 ). Our results indicated that in the absence of ligands, MR1 is retained mainly in the ER independently of its level of expression, which confirms that the limiting factor in determining ER retention or egress is ligand availability. As both cell lines and PBMCs npg A r t i c l e s retained most of their MR1 molecules in the ER, a notable conclusion from these obser vations is that human cells do not produce substantial amounts of endogenous MR1 ligands in the steady state, nor do they obtain these ligands from the extracellular environment (at least in blood).
To analyze in greater detail MR1 synthesis and trafficking in the absence or presence of ligand, we assessed conversion of MR1 from Endo H sensitive to resistant by metabolic radiolabeling (pulse) and chase experiments followed by immunoprecipitation, SDSPAGE and autoradiography. Newly synthesized MR1 molecules were Endo H sen sitive (Fig. 3d) and remained so in the absence of ligand for the next 24 h after the end of pulse (time 0). During this 24hlong chase period the amount of radiolabeled MR1 declined, indicative of degradation within the ER or via the ERassociated degradation (ERAD) pathway 20 . (A radiolabeled longlived protein just above the Endo H-resistant form of MR1 was nonspecifically immunoprecipitated with rabbit sera (NRS) (Fig. 3d) .) Addition of Ac6FP during the chase promoted con version of MR1 into the Endo H-resistant form (Fig. 3d) . We obtained similar results in cells incubated with 5OPRU instead of Ac6FP (Fig. 3e) . The Endo H-resistant MR1 molecules were sensitive to PNGase F (Fig. 3e) , an enzyme that removes carbohydrates from glyco proteins, which indicates that the posttranslational modification that distinguished Endo H-sensitive MR1 molecules from their resistant counterparts affected their carbohydrate moiety. The slow kinetics of degradation of radiolabeled MR1 in cells chased in the absence of VitB antigens ( Fig. 3d) is consistent with the conclusion that MR1 forms a stable pool of empty molecules in the ER. Immunoprecipitation of MR1 from cells that had not been incubated with ligands retrieved little or no β 2 microglobulin (β 2 m), the light subunit of MR1, indicat ing the molecules were nor fully folded and/or assembled. In contrast, the MR1 molecules immunoprecipitated from cells incubated with Ac6FP or 5OPRU were associated with β 2 m (Fig. 3a,b,d ). This suggested that ligand encounter within the ER induced changes in MR1 conformation and promoted stable binding of β 2 m.
MR1 folding requires Schiff base bonding with VitB antigen
The mAb 8F2.F9 reacts preferentially with fully folded MR1 mole cules 21 , so we used this reagent in immunoprecipitation and confocal microscopy experiments to assess the conformational state and location of MR1 in cells incubated with or without VitB antigens. Very little MR1 could be immunoprecipitated with 8F2.F9 from cells incubated without antigens, even though MR1CT, a rabbit serum specific for the cytosolic tail of folded or unfolded MR1 retrieved abundant MR1 (Fig. 4a) . However, little β 2 m coprecipitated with MR1 in these conditions (Fig. 4a) . Incubation of the cells with Ac6FP increased the amount of β 2 m bound to MR1 that could be immunoprecipitated with MR1CT (Fig. 4a) . Almost all of these MR1 molecules were now 8F2.F9 reactive and could also be immunoprecipitated with this mAb (Fig. 4a) . We examined the localization of MR1 in HeLa cells transfected with MR1 to enhance resolution of intracellular structures. No 8F2.F9reactive molecules were observed in cells incubated without MR1 ligands, but cells incubated with Ac6FP showed abundant 8F2.F9reactive MR1 on the plasma membrane (Fig. 4b) . Notably, when egress of MR1 from the ER was blocked with BFA, MR1 bound to β 2 m could still be immu noprecipitated with 8F2.F9 from cells incubated with Ac6FP (Fig. 4a) , and these molecules accumulated in the ER (Fig. 4b) . These results imply that Ac6FP can access the ER and bind MR1 there, causing a conformational change in MR1 characterized by stable association with β 2 m and acquisition of the 8F2.F9reactive fold.
We next asked what molecular mechanism triggers MR1 trafficking out of the ER in the presence of ligand. In crystal structures of TCR MR1VitB antigen, the VitB antigens are located in the A pocket of npg A r t i c l e s the MR1 ligand binding site, surrounded by aromatic residues 6, 7, 10, 12 .
At the base of this 'aromatic cradle' is MR1 K43, which forms a Schiff base (a covalent bond) with the ligands 6, 8 . Mutation of K43 to alanine (K43A) facilitates folding of recombinant MR1 in vitro 22 . We rea soned that neutralization of the positive charge at MR1 K43 within the ER via formation of a Schiff base with the ligand might serve as a molecular trigger for MR1 folding and trafficking. Indeed, the MR1K43A mutant molecule associated with β 2 m, acquired Endo H resistance and was expressed on the surface of C1R cells transfected with this mutant form of MR1, even in the absence of VitB anti gens (Fig. 4c,d ). We do not know whether the mutant molecule was expressed on the cell surface empty or bound to an endogenous ligand, but these findings demonstrate that MR1 remains incompletely folded within the ER unless its positively charged K43 is neutralized. We confirmed this making a second mutant form of MR1 at position 43, in this case exchanging the lysine for arginine. Although arginine has, like lysine, a long, positively charged side chain, its capacity to form a Schiff base is severely diminished 23 , so its positive charge cannot be neutralized by VitB antigens. C1R cells transfected with MR1K43R contained a similar amount of MR1 as cells transfected with the wildtype molecule (Fig. 4e) , but the mutant molecule did not become Endo H resistant and did not reach the cell surface even after incubation with VitB antigen (Fig. 4e,f) . In conclusion, in its free state, K43 prevents complete folding and causes ER retention of ligandfree MR1, but VitB antigen ligation serves as a 'molecular switch' that neutralizes the K43 positive charge, triggering complete MR1 folding around the ligand, association with β 2 m and egress of the trimeric complex to the cell surface.
Surface MR1 decreases independently of ligand affinity
We next addressed the fate of the MR1ligand complexes. Antigen presenting molecules on the cell surface are ultimately internalized by endocytosis. Upon reaching early endosomes, they encounter two nonexclusive fates-recycling back to the cell surface, possibly after reloading with new ligands acquired in endosomes, or trafficking to lysosomes for degradation. We incubated C1R.MR1 cells with or without ligands for 4 h and measured endocytosis of surface MR1 using a MR1specific mAb conjugated to a fluorescently labeled DNAbased internalization probe (fluorescence internalization probe (FIP) assay) 24 . This assay enables accurate measurements of surface molecule internalization across a wide range of expression 25 . Approximately 50% of surface MR1 was internalized within 2-4 h independently of association with ligand (Fig. 5a) . Microscopy con firmed transition of MR1 molecules labeled on the cell surface to intracellular structures within 1 h (Fig. 5b) . Some of these structures colabeled with early (EEA1 + ) or late (Lamp + ) endosomal markers, as expected (Fig. 5b) . The fraction of internalized MR1 that recycled back to the surface was very small and was also independent of VitB antigen binding (Fig. 5a) .
We wondered whether the few MR1 molecules that recycled back to the plasma membrane could efficiently present new ligands acquired during transit through endosomes, as do other antigenpre senting molecules, particularly MHC class II and CD1 (refs. 5,26) . This was a plausible hypothesis because, although MR1 and VitB antigens are covalently associated via a Schiff base, this link is labile at the moderately low pH (5-6) found in late endosomes. First we determined whether the MR1 molecules expressed by cells cultured without VitB antigens could bind ligands at the plasma membrane. This was the case, because incubation of such cells with 5OPRU for 20 min at 4 °C (to prevent internalization of surface molecules) led to formation of MR1-5OPRU complexes, detectable with TCR tetramer (Fig. 5c) . This result suggests that the small amount of MR1 expressed on the surface of cells not incubated with VitB antigens is 'empty' or bound to an unknown ligand of low affinity. In con trast, surface MR1 molecules that had already acquired 6FP ligands intracellularly were not receptive to 5OPRU binding on the cell surface, even though 5OPRU binds MR1 with higher stability than 6FP 10 (Fig. 5c) . We therefore tested whether these molecules could acquire ligands if they were allowed to undergo internalization and recycling. We incubated cells expressing MR1-6FP complexes with 5OPRU for 2 h at 37 °C. TCR tetramer staining confirmed for mation of MR1-5OPRU complexes in these conditions (Fig. 5d) , but the complexes could have originated at two locations: within the ER, where 5OPRU might bind newly synthesized MR1 molecules, or within the endocytic route, where 5OPRU might replace 6FP in molecules recycled from the cell surface. We treated the cells with BFA to block the ERderived source, finding that ~60% of the complexes generated during the assay required egress of molecules from the ER. This contrasted with the measurement of 5OPRU presentation by cells that had not been preincubated with 6FP (and expressed little MR1 on the surface): nearly all of the com plexes presented in these conditions were derived from an ER source (Figs. 1a and 5d ). In conclusion, once a sufficiently high number of MR1VitB antigen complexes have accumulated on the cell surface, these molecules can acquire and present new ligands via recycling. This is a pathway that may enable presentation of MR1 ligands that npg A r t i c l e s cannot efficiently reach the ER. Nevertheless, the contribution of this pathway to MAIT cell activation in vivo remains uncertain, as the ERbased pathway for MR1 presentation remains highly efficient even in cells that have already accumulated a large number of MR1VitB antigen complexes on their plasma membrane. Last, we investigated how removal of VitB antigen from the extracellular envi ronment affects the presentation of the ligand. Cells that had been incubated overnight with 5OPRU, washed then placed in new medium devoid of ligand started immediately to lose expression of MR1-5OPRU complexes, as indicated by tetramer staining (Fig. 5e) . Furthermore, surfacebiotinylated MR1 molecules bound to 5OP RU or to Ac6FP were steadily degraded over 8 h after removal of the ligands from the culture medium (Fig. 5f) , confirming that the rate of MR1VitB antigen turnover is independent of the affinity of the bound ligand. Therefore, the amount of VitB antigen presented by MR1 molecules is proportional to its availability for loading onto the molecules. Collectively, these findings illustrate that MR1 anti gen presentation is characterized by a rapid 'offonoff ' mechanism strictly dependent on antigen availability (Supplementary Fig. 4 ).
DISCUSSION
Peptides, lipids and small metabolites represent three classes of antigen that are presented by MHC, CD1 and MR1 molecules, respectively 1, 27, 28 . Each antigenpresenting molecule utilizes distinct strategies to obtain, capture and present antigens. Here we show that the MR1 antigen pres entation pathway has several distinct features. Unlike MHC and CD1 molecules, most of the MR1 molecules synthesized by a cell do not consti tutively associate with endogenous ligands (cytosolic peptides for MHC class I, Ii for MHC class II and lipids for CD1); instead, MR1 accumulates in the ER, in an incompletely folded conformation free of β 2 m. At this location, MR1 acts as an ERresident sensor of VitB antigens. Before encounter of such ligands, only a few MR1 molecules leave the ER and traffic to the cell surface, possibly via endocytic compartments, as npg suggested in previous studies 19 . These MR1 molecules can bind extra cellular ligands on reaching the plasma membrane, indicating they are expressed in an empty form or bound to lowaffinity endogenous ligands that can be readily replaced by VitB antigens. Nevertheless, the contribu tion of surface MR1 to VitB antigen presentation is very small. Most of the MR1VitB antigen complexes originate in the ER. This is another property that distinguishes MR1 from the two other molecules specialized in the presentation of extracellular antigens, namely MHC class II and CD1, which capture their ligands in endosomal compartments. Formation of MR1VitB antigens in the ER implies the existence of a yet uncharacterized pathway for transfer of VitB antigens to the ER lumen from the extracellular medium or the interior of phagosomes harboring bacteria. In the ER the VitB anti gens sponsor, via formation of a Schiff base bond, complete folding of MR1, association with β 2 m and trafficking of the ternary complex to the cell surface. Formation of a covalent bond (Schiff base) between MR1 and the ligands it presents is a third characteristic that distin guishes MR1 from the other antigenpresenting molecules.
All surface MR1VitB antigen complexes are reinternalized with similar kinetics regardless of ligand binding, and most of these mol ecules are degraded instead of recycled. Thus, the MR1 presentation pathway acts as a quick sensor of extracellular VitB antigens, enabling rapid activation of MAIT cells and maintenance of antigen presenta tion for as long as the VitB antigens remain in the extracellular envi ronment. Elimination of the source of VitB ligands is followed by a steady decline in the number of MR1antigen complexes exposed on the cell surface for MAIT cell recognition.
An implication of these findings is that the level of MR1 expression on the surface of cells in different anatomical location is directly propor tional to local antigen availability. Low MR1 expression on cells present in a sterile location, such as the blood (PBMCs), is consistent with this notion. It would be interesting to know whether such expression levels are sufficient to drive MAIT cell selection in the thymus. If they are not, it is possible that some antigenpresenting cells in the thymus express, or collect from the extracellular environment, MR1 selfligand capable of inducing a higher level of expression. Addressing this important ques tion will require analysis of thymic antigenpresenting cells.
In conclusion, the MR1 antigenpresentation pathway follows dis tinct rules that set it apart from the other mechanisms of antigen presentation in humans, namely those carried out by MHC and CD1 molecules. The results presented here provide a framework for future studies aimed at characterizing the machinery responsible for reten tion of ligandfree MR1 molecules in the ER, transport of extracellular VitB antigens to the ER and internalization and degradation of MR1 antigen complexes from the plasma membrane. The components of this machinery represent potential targets for therapeutic manipula tion of the MR1MAIT cell axis.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
Cell lines and transfectants expressing wild-type or mutant MR1. C1R and HeLa cell lines expressing MR1 under the control of the pMSCVIRESeGFP (pMIG) 29 vector were previously described 11 . The MR1K43A mutant was previously generated 11 and was also cloned into pMIG. A construct expressing MR1 or mutants thereof fused to enhanced GFP at the C terminus was generated by removing the IRESGFP segment of pMIG and cloning in the MR1GFP sequence. These constructs were transduced into C1R cells and sorted on the basis of GFP expression level as a surrogate marker of MR1 expression. As cell culture medium is a source of folatederived MR1 ligands 7 , cells were cultured in folatefree RPMI (Life Technologies) during experimen tal procedures but were otherwise maintained in folatesufficient medium.
Human samples and ethics. Blood from healthy human donors was acquired from the Australian Red Cross Blood Service with informed consent from donors, and ethics approval was obtained from the University of Melbourne Human Research and Ethics Committee (number 1035100) and the Red Cross. Peripheral blood mononuclear cells (PBMCs) were purified by standard density gradient (FicollPaque Plus; GE Healthcare) and used immediately without storage.
Antibodies. For flow cytometry staining of MR1, the mAb 26.5 (ref. 30 ) was used, except in primary human cells, where significant nonspecific staining was observed with this clone. In this case the 8F2.F9 mAb 21 was used. MHC class I was measured by flow cytometry using anti-HLA class I-APC conjugate (clone Tü149; Life Technologies). A polyclonal rabbit antiserum was gener ated against a peptide corresponding to the final 15 residues of human MR1 cytosolic tail (PREQNGAIYLPTPDR) (anti-MR1CT; Abmart). For immu noblot detection of β 2 microglobulin, clone BBM.1 was used. The following antibodies were used to stain human PBMCs: antiCD19-FITC (BD; clone HIB19); antiCD3-Pacific blue (BD; clone UCHT1); antiCD14-Brilliant Violet 570 (BioLegend; clone M5E2); antiTRAV12APC (BioLegend; clone 3C10). MAIT cells were stained with PElabeled tetrameric human MR1-5OPRU at 0.7 µg/ml. For intracellular cytokine staining, cells were fixed for 20 min on ice with 1% PFA and 2% glucose in PBS, then permea bilized and stained in 0.3% saponin in PBS with anti-TNFα-Pacific blue (BioLegend; clone mAb11) overnight. MR1 ligands. MR1 ligands Ac6FP (Schircks Laboratories) and 5OPRU (5ARU 6 and methylglyoxal (pyruvaldehyde; SigmaAldrich) at equimolar concentrations) were added to the culture medium at the concentrations indicated in the figures.The inhibitors CHX and BFA (Abcam) were used at 20 µg/ml and 10 µg/ml, respectively.
Flow cytometry analysis of MR1 surface expression. C1R cells, freshly puri fied PBMCs from healthy donors, and normal human bronchial epithelial cells (Lonza) were cultured with ligands and/or inhibitors. Cells were stained with the respective biotinylated mAbs followed by PEconjugated streptavi din (BioLegend) and detected by flow cytometry. Propidium iodide was used to exclude dead cells. To demonstrate specific binding to MR1 in primary cells, the mAb 8F2.F9 was blocked by preincubating with recombinant soluble human MR1-5OPRU generated as previously described 6 (10:1 molar ratio). To measure surface expression of MR1-5OPRU complexes, a MAIT TCR tetramer was generated from TRBV61 + MAIT TCR (clone AF7) 31 , conjugated to streptavidinPE and used at 5 µg/ml. Briefly, TCR αchain was mutated to express a Cterminal cysteine, TCR α and βchains were expressed, refolded and purified as described previously 10, 12 then biotinylated using the EZLink MaleimidePEG2Biotin Kit (Thermo Fisher). Biotinylated TCR was isolated from nonbiotinylated species by MonoQ anion exchange chromatography and conjugated to streptavidinfluorochrome (BD).
Salmonella Typhimurium strains. Bacterial infections were carried out with Salmonella enterica var. Typhimurium (STM) 'wildtype' strain SL1344 (ref. 32) . For the liganddeficient strain (HW101), the riboflavin synthesis genes ribDH were deleted (∆ribDH) on an SL1344 background by lambda Red recombinasemediated allelic replacement 33 followed by general transduction using phage P22 as described 34 , and grown in medium supplemented with 20 µg/ml riboflavin. Strains carrying stable chromosomal expression of mCherry were generated using P22mediated phage transduction of mCherry chromosomal integrants.
MAIT cell activation assays. C1R cells were infected for 1 h at multiplicity of infection (MOI) 50 then washed and cultured for up to 6 h in the presence of gentamycin (40 µg/ml). For the comparison of MR1 surface expression and activation for a range of 5OPRU concentrations, C1R cells incubated with titrating amounts of 5OPRU were fixed for 20 min on ice with 1% PFA and 2% glucose in PBS then washed three times with medium and cultured with Jurkat cells transduced with a MAIT TCR 7 (Jurkat.MAIT) overnight.
For human PBMC activation assays, whole PBMCs were cultured in plastic plates for 2 h, then nonadherent cells were removed and cultured overnight until the activation assay. Adherent PBMCs were washed and infected with STM strains for 5 h in the presence or absence of BFA (10 µg/ml) or CHX (20 µg/ml), after which they were fixed as described above and incubated with the matching nonadherent PBMCs from the same donor for 1 h, then for another 6 h in the presence of BFA.
Immunoprecipitation and cell surface biotinylation. For immunoblotting and detection of MR1, cells were lysed in 0.5% IGEPAL CA630 (Sigma Aldrich), 50 mM TrisHCl (pH 7.4), 5 mM MgCl 2 with Complete Protease Inhibitor Cocktail (Roche), and nuclei were separated by centrifugation at 13,000 × g for 10 min. Lysates were precleared with normal rabbit serum (SigmaAldrich) and protein G-Sepharose then with protein G-Sepharose alone. MR1 was immunoprecipitated using anti-MR1CT and protein G-Sepharose, and precipitates were washed three times with NET buffer (0.5% IGEPAL CA630, 50 mM TrisCl pH 7.4, 150 mM NaCl, 5 mM EDTA) and treated with Endoglycosidase Hf (New England Biolabs) per the manufac turer's instructions. Proteins were denatured with reducing SDSPAGE sample buffer, separated on NuPAGE 4-12% BisTris precast gels (Life Technologies) and immunoblotted onto nitrocellulose membranes using the iBlot system (Life Technologies). To detect MR1 in primary human PBMCs, 100 million cells were used per immunoprecipitation reaction, whereas for C1R.MR1 cells only 1 million cells were required. For biotinylation of cell surface proteins, cells were washed twice in PBS (pH 8) and resuspended in the cellimpermeable EZlink SulfoNHSBiotin (0.25 mg/ml, PBS, pH 8; Thermo Scientific) for 30 min on ice. Cells were washed in 0.1 M glycine in PBS twice then lysed as above and immunoprecipitated using streptavidin agarose (Pierce).
Radiolabeling. Cells were starved for 30 min in methionine and cysteinefree DMEM, then pulsed for 30 min in this medium supplemented with 35 Slabeled methionine and cysteine (Express Protein Labeling Mix, Perkin Elmer) at 200 µCi/ml. Cells were washed and then chased in folatefree RPMI1640 then washed in PBS and frozen. Cells were lysed and immunoprecipitated as described above with an additional preclear step of protein G-Sepharose. Precipitates were washed three times in NET buffer containing 0.2% SDS, and treated with endoglycosidase Hf or PNGase F (New England Biolabs) per the manufacturer's instructions. Proteins were separated by 11.5% SDSPAGE, and gels were rinsed in DMSO and then in 22% 2,5diphenyloxazole in DMSO fol lowed by water, then dried and exposed to Hyperfilm MP (GE Healthcare).
Confocal microscopy. For imaging MR1GFP in C1R cells, after overnight culture with Ac6FP, cells were washed once in HBSS and incubated with 200 nM ERTracker BlueWhite DPX (Life Technologies) for 15 min at 37 °C, washed and imaged live using a Zeiss LSM710 confocal microscope.
HeLa.MR1 cells were grown overnight on LabTek chamber slides (Nunc) and fixed after treatments with 4% PFA in PBS. Cells were blocked and per meabilized with 10% normal donkey serum and 0.05% saponin, and incubated with primary antibodies diluted in blocking buffer against MR1 (mAb 8F2.F9 2 µg/ml) and rabbit antiGRP78 BiP (Abcam, 1:200). After two washes in PBS, Alexa Fluor 568-conjugated antirabbit IgG and Alexa Fluor 647-conjugated antimouse IgG in blocking buffer were added. Cells were then washed in PBS and incubated with DAPI (1 µg/ml) for 5 min then mounted in 90% glycerol, 20 mM TrisHCl, pH 8, 0.2 M DABCO (SigmaAldrich).
For visualizing endocytosed MR1 HeLa.MR1, cells were incubated with Ac 6FP for 16 h, then surface MR1 was labeled with Alexa Fluor 647-conjugated npg
